Harrow Acquires Global Rights to TYRVAYA®, the First and Only FDA-Approved Nasal Spray for Dry Eye Disease

Harrow has secured exclusive global rights to TYRVAYA®, a first-mover FDA-approved nasal spray for dry eye disease, through acquisition from Viatris. This represents a material portfolio expansion for Harrow's ophthalmic franchise, consolidating control over a differentiated treatment modality in a high-prevalence condition affecting millions globally.

The strategic rationale centers on market concentration and revenue synergy. Dry eye disease remains underserved despite significant patient populations; TYRVAYA's novel cholinergic agonist mechanism differentiates it from traditional tear substitute therapies. Current approvals in the U.S., China, and Taiwan provide near-term revenue floors, while pending applications in other geographies offer multi-year growth optionality without additional R&D investment.

For Harrow, the acquisition reduces competitive risk and enhances pricing power within its ophthalmic disease management platform. For Viatris, the divestiture allows capital reallocation and portfolio optimization toward higher-margin assets. The deal structure signals confidence in DED's commercial trajectory despite a competitive landscape.

Sector implication: Health Care, particularly specialty ophthalmology, benefits from consolidation-driven efficiency and market concentration. The deal underscores investor appetite for niche therapeutic assets with established regulatory pedigree, supporting valuations for pure-play ophthalmology players.